Matt Posard

Shares of TrovaGene Inc (NASDAQ: TROV), a development-stage molecular diagnostic company, were trading higher by nearly 20 percent on Monday after the company announced that it has entered into an agreement with FedMEd, a proprietary Preferred Provider Organization consisting of over 550,000...